While there is no standardized treatment protocol for BRG-1-deficient lung cancer, numerous preliminary clinical studies have provided new opportunities for treating these tumors, including platinum-based chemotherapy drugs and immune checkpoint inhibitors (ICIs). This evidence concerns the gene SMARCA4 and lung carcinoma.